The global hydroxychloroquine market is projected to expand rapidly through the end of the decade, according to a new analysis from Kings Research. The market was valued at USD 900.1 million in 2023 and is expected to grow from USD 1,091.5 million in 2024 to USD 5,055.1 million by 2031, exhibiting a CAGR of 24.48% during the forecast period. Growth is driven by the drug’s widespread use in treating autoimmune conditions such as rheumatoid arthritis and lupus erythematosus, along with expanding access to prescription medicines in emerging economies.
Market Overview
The market encompasses the production, distribution, and consumption of hydroxychloroquine across the pharmaceutical and healthcare sectors. It includes manufacturers, suppliers, and healthcare providers who use the drug for autoimmune diseases such as lupus and rheumatoid arthritis, as well as for malaria and certain off-label applications. Rising global prevalence of chronic autoimmune disorders has increased demand for long-term disease management, positioning hydroxychloroquine as a key therapeutic agent.
Growing awareness among healthcare professionals and patients about the benefits of early and sustained treatment with disease-modifying antirheumatic drugs is another supporting factor. Expanding healthcare infrastructure and improved access to prescription medications in emerging markets are lifting consumption, while advances in formulation and distribution have streamlined access and improved patient compliance. Ongoing clinical research into potential uses in other inflammatory and infectious diseases continues to generate interest.
Key Highlights from the Report
- The market was valued at USD 900.1 million in 2023 and is projected to grow at a CAGR of 24.48% from 2024 to 2031.
- North America held a 36.12% share in 2023, valued at USD 325.1 million.
- The rheumatoid arthritis segment generated USD 306.9 million in revenue in 2023.
- The tablet segment is expected to reach USD 4,071.5 million by 2031.
- The hospital pharmacies segment is expected to reach USD 1,998.9 million by 2031.
- Asia Pacific is anticipated to grow at a CAGR of 26.78% over the forecast period.
Growth Driver: Aging Populations and Expanding Healthcare Access
The rising global geriatric population and increased healthcare spending in emerging economies are the main forces behind market growth. As the population aged 60 and above expands, particularly in developed and middle-income countries, the prevalence of chronic autoimmune conditions such as rheumatoid arthritis and lupus is expected to increase. That trend is expected to drive substantial demand for long-term therapies aimed at managing inflammation and immune response. In June 2023, the World Health Organization highlighted that rheumatoid arthritis affects approximately 18 million people worldwide and emphasized improving access to treatment, rehabilitation services, and assistive products.
Emerging economies are also investing heavily in healthcare. Governments are expanding insurance coverage, upgrading hospital infrastructure, and promoting local pharmaceutical manufacturing to prioritize access to essential medicines. These efforts narrow the treatment gap for chronic diseases and increase access to affordable hydroxychloroquine therapy, improving the market outlook.
Market Challenge: Price Volatility and Competitive Pricing Pressure
Price volatility and competition from generics present the main challenge. Although hydroxychloroquine is widely available as a generic drug, the price can vary significantly across regions and suppliers, influenced by raw material costs, manufacturing expenses, and negotiations with healthcare providers and insurers. A growing presence of generic manufacturers adds pricing pressure, affecting margins and complicating pricing strategies.
To respond, companies are adopting cost-efficiency strategies such as optimizing supply chain management and reducing manufacturing overheads. Strategic partnerships and long-term supplier contracts can help stabilize raw material costs and ensure more predictable pricing.
Market Trend: Clinical Research and Digital Pharmacy Channels
Two developments define current market evolution. The first is an increase in clinical trials exploring efficacy beyond traditional indications. Researchers are investigating potential roles in neurodegenerative diseases, cancer, and metabolic disorders. The second is the rapid adoption of online and telehealth pharmacy services, which is widening the global distribution network. E-prescriptions and virtual consultations have made medication more accessible, especially in remote and underserved regions, while faster delivery timelines and automated refill systems improve adherence and reduce reliance on traditional brick-and-mortar pharmacies. These changes offer manufacturers and distributors new channels for growth and market penetration.
Segmentation Analysis
By disease indication, the market covers rheumatoid arthritis, lupus erythematosus, malaria, residual COVID-19 use, and others. Rheumatoid arthritis earned USD 306.9 million in 2023, reflecting rising autoimmune prevalence and the drug’s established role as a first-line treatment.
By formulation, the market is divided into tablets, injections, and suspensions. Tablets held an 80.12% share in 2023, supported by widespread availability, ease of administration, and patient preference for oral dosage forms, and are projected to reach USD 4,071.5 million by 2031. By distribution channel, the market includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are projected to reach USD 1,998.9 million by 2031 as hospitalization rates rise and institutions play a larger role in chronic disease treatment.
Regional Analysis
North America accounted for 36.12% of the market in 2023, valued at USD 325.1 million. The high prevalence of autoimmune diseases such as lupus and rheumatoid arthritis in the United States, an advanced healthcare infrastructure, high diagnostic rates, and a strong presence of branded and generic manufacturers all contribute. Continuous clinical research by U.S. institutions, robust insurance coverage, specialized rheumatology centers, and favorable reimbursement practices further sustain demand. A February 2025 UCLA-led study found that U.S. outpatient prescriptions for hydroxychloroquine and ivermectin rose two- to ten-fold from pre-pandemic levels for COVID-19 treatment despite substantial clinical evidence disproving their efficacy, underscoring the need for evidence-based prescribing.
Asia Pacific is expected to register the fastest CAGR at 26.78%, with a forecast value of USD 1,384.6 million by 2031. Rising awareness of autoimmune disorders, growing healthcare spending, and an expanding middle class are fueling growth. India and China, with large patient pools and improving access to care, play significant roles, and India is both a key consumer and a leading global supplier thanks to its cost-effective manufacturing base. Urbanization, better diagnostic practices, and the expansion of retail pharmacy networks and e-pharmacy platforms are accelerating regional penetration.
Regulatory Frameworks
In the United States, hydroxychloroquine is regulated by the Food and Drug Administration as a prescription medication, with guidance on Good Manufacturing Practices and labeling. In the European Union, the European Medicines Agency governs its use, and the Committee for Medicinal Products for Human Use evaluates safety, efficacy, and quality. China’s National Medical Products Administration approves the drug under national drug standards and the Chinese Pharmacopoeia. In Japan, the Pharmaceuticals and Medical Devices Agency applies GMP and GCP guidelines. In India, the Central Drugs Standard Control Organization regulates the drug under the Drugs and Cosmetics Act, 1940, for malaria, rheumatoid arthritis, and lupus.
Competitive Landscape
The industry combines established pharmaceutical manufacturers with emerging generic producers. Leading players are expanding production capacity to meet fluctuating global demand, particularly in regions with high disease prevalence, and emphasize cost-effective manufacturing and supply chain optimization to maintain competitive pricing and uninterrupted availability. Vertical integration to control raw material sourcing, partnerships with regional distributors and healthcare providers, and strategic acquisitions are common approaches to broaden market presence. Companies are also investing in research and development to improve formulations, such as modified-release versions and combination therapies, with the aim of enhancing patient compliance.
Key companies profiled include Sanofi, Mylan N.V., Teva Pharmaceuticals USA, Inc., Zydus Group, Dr. Reddy’s Laboratories, Inc., Apotex Inc., Hanlim Pharm. Co. Ltd., Cipla, Torrent Pharmaceuticals Ltd., McW Healthcare Pvt. Limited, Fermion Oy, Tamin Pharmaceutical Investment Company, Tagoor Laboratories Pvt. Ltd., SCI Pharmtech, Inc., and Novalab Healthcare.
Strategic Implications for Stakeholders
For manufacturers, the report suggests that scale and cost discipline will matter as much as clinical positioning. Because the product is a widely available generic, differentiation is more likely to come from reliable supply, regulatory compliance, vertical integration, and relationships with distributors and hospital systems. For distributors and pharmacy operators, the growth of online and telehealth channels points to new models of fulfillment and adherence support, particularly for patients on long-term therapy. For healthcare providers and policymakers, the report is a reminder that prescribing should follow clinical evidence, as the UCLA-led findings on COVID-19 use illustrate. Investors will want to pay particular attention to Asia Pacific, where demand growth, domestic manufacturing strength, and expanding pharmacy networks converge. Ultimately, the market’s trajectory will hinge on how well participants balance affordability, supply security, and responsible, evidence-based use across the indications that drive demand.
Outlook
The report points to a market whose growth will be shaped by demographics, access, and distribution. An aging global population and a growing autoimmune disease burden create durable demand, while e-pharmacy and telehealth channels extend reach in underserved areas. Asia Pacific, led by India and China, is expected to grow faster than any other region, and tablets will continue to account for the large majority of revenue. At the same time, producers will need to navigate generic competition and price volatility through efficient manufacturing, supply security, and differentiated formulations.
Stakeholders such as manufacturers, distributors, healthcare providers, and investors can use the full report, released in April 2025 and spanning 170 pages, to assess segment opportunities, regional dynamics, and regulatory considerations.
About Kings Research
Kings Research is a market research and consulting firm, part of One Media Group, that delivers data-driven intelligence and strategic guidance to help organizations identify, evaluate, and capitalize on market opportunities across industries. Its reports combine quantitative market sizing with qualitative analysis of drivers, challenges, trends, regulatory frameworks, and competitive landscapes.
Media Contact: Kings Research, 5348 Vegas Dr. Suite 305, Las Vegas, NV 89108. Email: business@kingsresearch.com
